Bristol Myers Gets Speedy FDA Review for Iberdomide in Multiple Myeloma
Bristol Myers Gets Speedy FDA Review for Iberdomide in Multiple Myeloma is drawing significant interest across the industry.
By Colin Kellaher Bristol Myers Squibb said the U.S. Food and Drug Administration has granted priority review to its application seeking approval of its iberdomide drug candidate in certain...
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Empirical Spine: FDA Grants PMA Approval to LimiFlex Dynamic Sagittal Tether
- Republican AGs Urge DOJ to Scrutinize Netflix-Warner Deal
- Texas is suing TP-Link over its ties to China
- With Mohammed Usman out, Ex-UFC title challenger replaces him in Gamebred FC heavyweight tournament
Source: Original →